Business Wire

UPL-LTD.

4.10.2021 14:38:08 CEST | Business Wire | Press release

Share
UPL Ltd. Joins The Climate Pledge, Furthering a Commitment to Reshape the Role of Global Agriculture in the Fight Against Climate Change

UPL Ltd. (NSE: UPL & BSE: 512070) has announced that it has joined The Climate Pledge (‘TCP’). UPL joins as the Pledge’s first signatory from the agricultural inputs, solutions, and technologies sector.

The Climate Pledge was co-founded by Amazon and Global Optimism in 2019, and it’s a commitment to reach net-zero carbon by 2040, and meet The Paris Agreement 10 years early. As of September 2021, The Climate Pledge has more than 200 signatories across 26 industries and 21 countries.

UPL is a global provider of sustainable agriculture products and solutions, bringing biologicals and traditional crop protection solutions to more than 138 countries around the world. UPL is reimagining sustainability through OpenAg, feeding sustainable growth for all – no limits, no borders. With farmers at our centre, we are building a network that redefines the way the entire industry thinks and works – open to innovative ideas and new answers as we strive to make every single food product more sustainable.

Jai Shroff, Global CEO of UPL Ltd., said:

“At UPL we believe that global agriculture is about to play its most important role yet – having first nourished the planet with abundant food, it will now sustain us through a transformational role tackling climate change. Achieving this will rely on reimagining sustainability through the power of partnerships, and by joining The Climate Pledge we are reinforcing our commitment to collaboration, to sustainability, and to leadership in our industry. We are excited to join a community that will share knowledge, ideas, and best practices.”

“The recent report released by the IPCC is the starkest warning yet that the systems supporting human life are reaching tipping points and that the window of time to act decisively is narrowing,” said Christiana Figueres, the UN’s former climate chief and now founding partner of Global Optimism. “This wake up call from science must be faced with courage and conviction. In this light, it’s encouraging that 86 more companies – some of the largest household names in the world – are now joining The Climate Pledge, committing to accelerate their actions to tackle climate change in a timely fashion, and playing their part in building a low-carbon economy. I look forward to the fruits of the leadership we will see from this collective of 200 signatories that are now part of The Climate Pledge.”

Joining TCP emphasizes on a wider commitment led by UPL to reimagine sustainability, and transform the role of agriculture as a positive contributor to meeting the challenges presented by climate change, food security, biodiversity loss, and water scarcity. In addition, over the last 5 years UPL has reduced its carbon emissions by 26% and has taken a goal to reduce our carbon emissions by an additional 25% by 2025. UPL has made extensive use of sustainability-linked loans as a part of our capital structure to ensure that the link between actions and its impact is clearly established.

UPL’s commitment to TCP builds on the company’s existing memberships and associations through which it continues to reimagine sustainability, including as members or signatories of: The Food and Land Use Coalition; United Nations Global Compact; World Business Council for Sustainable Development; World Economic Forum: Food Action Alliance; IGD; International Food and Policy Research Institute; World Cocoa Foundation; Cocoa and Forests Initiative; European Cocoa Association.

Notes to Editors:

About UPL

UPL Ltd. (NSE: UPL & BSE: 512070) is a global provider of sustainable agriculture products & solutions, with annual revenue exceeding $5.2 billion.

About The Climate Pledge

In 2019, Amazon and Global Optimism co-founded The Climate Pledge, a commitment to reach the Paris Agreement 10 years early and be net-zero carbon by 2040. Now, 201 organizations have signed The Climate Pledge, sending an important signal that there will be rapid growth in demand for products and services that help reduce carbon emissions. For more information, visit www.theclimatepledge.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/UPLGlobal/?ref=bookmarks

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release

Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release

Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly

SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release

The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter

Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release

Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye